

P24170.A01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Viswanathan SRINIVASAN et al.

Confirmation No. 4047

Serial No. : 10/736,902

Group Art Unit: 1616

Filed : December 17, 2003

For : DOSAGE FORM CONTAINING PROMETHAZINE AND ANOTHER DRUG

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents:

- (1) U.S. Patent No. 4,642,231 (PETERS et al.), February 10, 1987;
- (2) U.S. Patent No. 5,807,579 (VILKOV et al.), September 15, 1998;
- (3) U.S. Patent No. 6,491,949 B2 (FAOUR et al.), December 10, 2002;
- (4) U.S. Patent No. 4,777,170 (HEINRICH), October 11, 1988;
- (5) U.S. Patent No. 4,762,709 (SHEUMAKER), August 9, 1988;
- (6) U.S. Patent No. 6,001,392 (WEN et al.), December 14, 1999;
- (7) U.S. Patent No. 6,372,252 B1 (BLUME et al.), April 16, 2002;

P24170.A01

- (8) U.S. Patent Application Publication No. U.S. 2003/0049318 (DAVIS et al.), March 13, 2003;
- (9) Text of the Novahistine LP Sales Meeting - Part One, pp. 19-34, December 1957.


A copy of the above-listed document (9) is enclosed together with a completed copy of the PTO-1449 Form listing the above-listed documents (1) to (9). Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. § 1.98 (a)(2)(I), copies of the U.S. patents and the published U.S. application cited above are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.


P24170.A01

Respectfully submitted,
Viswanathan SRINIVASAN et al.

A handwritten signature in black ink, appearing to read "Stephen M. Roylance", written over a horizontal line.

Stephen M. Roylance
Reg. No. 31,296.

April 22, 2004
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P24170Serial No.
10/736,902

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Viswanathan SRINIVASAN et al.Filing Date
December 17, 2003Group
1616**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4	6	4	2	2	3	1	02/10/87	PETERS et al.			
		5	8	0	7	5	7	9	09/15/98	VILKOV et al.			
		6	4	9	1	9	4	9	12/10/02	FAOUR et al.			
		4	7	7	7	1	7	0	10/11/88	HEINRICH			
		4	7	6	2	7	0	9	08/09/88	SHEUMAKER			
		6	0	0	1	3	9	2	12/14/99	WEN et al.			
		6	3	7	2	2	5	2	04/16/02	BLUME et al.			
	2003 /	0	0	4	9	3	1	8	03/13/03	DAVIS et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1	Text of the Novahistine LP Sales Meeting - Part One, pp. 19-34, December 1957.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.